Phase I/II Study of G3139 (Bcl-2 Antisense Oligonucleotide) in Combination with Doxorubicin and Docetaxel in Breast Cancer

PURPOSE: Preclinical data showed enhancement of breast cancer cell death when G3139 was combined with anthracyclines and taxanes. We evaluated the efficacy and safety of a Bcl-2 antisense oligonucleotide, G3139, in combination with doxorubicin (A) and docetaxel (T) in patients with locally advanced...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Moulder, Stacy L., Symmans, W. Fraser, Booser, Daniel J., Madden, Timothy L., Lipsanen, Cindy, Yuan, Linda, Brewster, Abenaa M., Cristofanilli, Massimo, Hunt, Kelly K., Buchholz, Thomas A., Zwiebel, James, Valero, Vicente, Hortobagyi, Gabriel N., Esteva, Francisco J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2008
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4375958/
https://ncbi.nlm.nih.gov/pubmed/19047121
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-1104
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados